• Pressemitteilung BoxID 499835

Genentech and Pfizer Share CDx Success Insights at the 4th Molecular Diagnostics for Cancer Drug Development in Boston

(PresseBox) (London, UK, ) The final agenda has been released for the 4th Molecular Diagnostics for Cancer Drug Development meeting (Boston, June 25th - 28th 2012).

The 3 day agenda features 31 expert speakers including the key project leaders of Zelboraf (Genentech) and Xalkori (Pfizer) on overcoming the scientific and commercial hurdles of targeting a drug to a specific patient subpopulation, and how they gained regulatory approval of their companion diagnostics last year.

They join oncology and diagnostics experts representing: Clovis Oncology, MD Anderson Cancer Center, Johnson & Johnson, National Cancer Institute, Astellas Pharma, Fred Hutchinson Cancer Research Center, The Biomarkers Consortium, Novartis, Daiichi-Sankyo, FDA, ImmunoGen, Bristol-Myers Squibb, Morphotek, Eisai, Bayer, Dana-Farber Cancer Institute, AVEO Pharmaceuticals, Celgene and Merck.

Visit the event website or download the brochure to see the full speaker line up and agenda.

Diese Pressemitteilungen könnten Sie auch interessieren

Leistungsstellenmanagement mit dem KIS: Neutrale Koordination als Erfolgsgarant

, Medizintechnik, Adiccon GmbH

Eine Leistungsstelle im Krankenhaus erbringt Leistungen im Rahmen einer medizinischen Behandlung z.B. bei einer Magenspiegelung, beim EKG, bei...

Sport im Winter: Leichtes Training beugt Infektionen vor

, Medizintechnik, TÜV Rheinland

Dreimal wöchentlicher Ausdauersport stärkt die Abwehrkräfte und das Herz-Kreislauf-System. Im Sommer ist das regelmäßige Training im Freien für...

BIOTRONIK Releases New Online Tool to Track MR Conditional Status of Implantable Devices

, Medizintechnik, BIOTRONIK

BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced the launch of ProMRI® SystemCheck, a new online tool for tracking...

Disclaimer